www.sciencedaily.com
Novo Nordisk’s oral semaglutide 25 mg demonstrated impressive weight loss, up to 16.6%, in a significant study, comparable to the injectable Wegovy. Beyond weight reduction, the oral medication improved cardiovascular health and boosted physical activity. Its safety profile mirrors existing semaglutide treatments, making it a potentially game-changing option for patients who prefer taking a pill over injections. Experts hail this advancement as a major breakthrough for individuals seeking effective and convenient weight management solutions.
